Cytosorbents (NASDAQ:CTSO) Posts Earnings Results, Misses Estimates By $0.04 EPS

Cytosorbents (NASDAQ:CTSO) posted its quarterly earnings results on Wednesday, March 25th. The medical research company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04), Zacks reports. Cytosorbents had a negative net margin of 22.12% and a negative return on equity of 150.53%.

Here are the key takeaways from Cytosorbents’ conference call:

• Full‑year revenue was up 4% to $37.1M with record core product sales, driven by double‑digit growth in international direct sales (+13%) and distributor sales (+11.4%) but partially offset by a 10% decline in Germany due to a commercial restructuring.
• Gross margins strengthened to 71% for the year and 74% in Q4, driven by manufacturing efficiencies that support improved profitability and lower production spend going into 2026.
• DrugSorb‑ATR faces regulatory uncertainty after an initial de novo denial, but the appeal found no safety concerns, FDA discussions are ongoing for a targeted resubmission, and the STAR‑T randomized trial was published showing safety and reduced bleeding.
• Management has reduced costs (including a Q4 restructuring), improved operating and adjusted EBITDA losses, and expects operating cash‑flow breakeven in the second half of 2026 while carrying $7.8M in cash as of year‑end.
• Commercial innovations—>100 placements of the standalone PuriFi pump and the new HotSwap cartridge‑exchange—are intended to expand access, enable earlier intervention, and drive incremental recurring disposable cartridge usage.

Cytosorbents Trading Down 2.6%

NASDAQ:CTSO traded down $0.02 during trading hours on Wednesday, hitting $0.57. 92,729 shares of the company were exchanged, compared to its average volume of 78,253. The stock has a market capitalization of $35.78 million, a price-to-earnings ratio of -4.39 and a beta of 1.43. The company has a current ratio of 2.13, a quick ratio of 1.58 and a debt-to-equity ratio of 2.82. Cytosorbents has a one year low of $0.50 and a one year high of $1.39. The company has a fifty day simple moving average of $0.65 and a 200 day simple moving average of $0.68.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. CIBC Bancorp USA Inc. acquired a new stake in Cytosorbents during the 3rd quarter worth about $161,000. Avenir Corp lifted its stake in shares of Cytosorbents by 2.9% in the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after purchasing an additional 147,261 shares during the period. Vanguard Group Inc. lifted its stake in shares of Cytosorbents by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after purchasing an additional 79,535 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 37,519 shares in the last quarter. Finally, Citadel Advisors LLC boosted its position in shares of Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after purchasing an additional 36,790 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Wall Street Analysts Forecast Growth

CTSO has been the topic of a number of research reports. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a research note on Wednesday, April 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.38.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.